Company Information
Address 9130 RED BRANCH RD STE X
COLUMBIA, MD, 21045-2006



DUNS: 963442723

# of Employees: 27

Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N

Award Charts

Award Listing

  1. A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer

    Amount: $152,589.00

    Significance Despite decreases in the overall number of new breast cancer BC cases reported in the US annually there are still about BC deaths annually from metastatic breast cancer ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Targeted Therapy for Non Small Cell Lung Carcinoma Human Phase safety and dose escalation studies

    Amount: $1,154,726.00

    Significance In new cases of LC and related deaths are expected in the US Of new LC cases are non small cell lung cancer NSCLC and of these are diagnosed with metast ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health

    Amount: $1,000,000.00

    Not Available

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  4. Title: Development of Novel Anticancer Agent to potentiate sensitivity to anti-estrogen therapy PoP: 09/19/2014 to 09/18/2016

    Amount: $1,478,552.00

    Not Available

    SBIRPhase II2014Department of Health and Human Services
  5. IGF::OT::IGF Title: SMART Fusion: High Affinity Peptide Capture Reagents PoP: 0

    Amount: $199,828.00

    The purpose of this application is to develop realiable, renewable, cost effective, specific, high affinity antipeptide affitnity reagent to be successfully used in mass spec based cancer biomarker de ...

    SBIRPhase I2013Department of Health and Human Services
  6. Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies

    Amount: $193,879.00

    DESCRIPTION (provided by applicant): Lung Cancer remains the leading cause of cancer and mortality for men and women worldwide. In 2010, there were 222,520 new cases of lung cancer diagnosed in t ...

    SBIRPhase I2012Department of Health and Human Services

    Amount: $199,380.00

    Aromatase Inhibitors (AI) are the preferred hormonal treatment for estrogen receptor positive Breast Cancer (BC) in postmenopausal women and are used to treat approximately 140,000 patients annually i ...

    SBIRPhase I2012Department of Health and Human Services
  8. Serum GP88 biomarker as a surrogate marker for disease progression in breast canc

    Amount: $113,320.00

    DESCRIPTION (provided by applicant): 40,000 women die annually in the US as a result of breast cancer (BC). Although BC can be controlled if detected early, a significant number is not detected until ...

    SBIRPhase I2011Department of Health and Human Services
  9. Novel Targeted Therapy for Breast Cancer

    Amount: $1,153,870.00

    DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side eff ...

    SBIRPhase II2010Department of Health and Human Services
  10. Novel Small Molecule Inhibitor of Rheumatoid Arthritis

    Amount: $184,029.00

    DESCRIPTION (provided by applicant): Lck is a Src family non-receptor tyrosine kinase expressed by T lineage lymphocytes. In T cells, Lck plays an essential role in the generation of antigen-mediated ...

    SBIRPhase I2009Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government